Jeremy Day
A5026484637- Fungal Infections and Studies
- Antifungal resistance and susceptibility
- Nail Diseases and Treatments
- Infectious Diseases and Tuberculosis
- COVID-19 Clinical Research Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Tuberculosis Research and Epidemiology
- Hepatitis C virus research
- Bacterial Infections and Vaccines
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Plant Pathogens and Fungal Diseases
- HIV/AIDS drug development and treatment
- Pneumonia and Respiratory Infections
- Salmonella and Campylobacter epidemiology
- Orthopedic Infections and Treatments
- Mycobacterium research and diagnosis
- Infective Endocarditis Diagnosis and Management
- Respiratory Support and Mechanisms
- Cytomegalovirus and herpesvirus research
- Intensive Care Unit Cognitive Disorders
- Neurological disorders and treatments
- Hereditary Neurological Disorders
Oxford University Clinical Research Unit
2015-2024
University of Oxford
2015-2024
Royal Devon and Exeter Hospital
2023-2024
Angkor Hospital for Children
2013-2022
Hospital for Tropical Diseases
2006-2022
University of Dundee
2021
Medical Research Council
2021
National Health and Medical Research Council
2021
Evidence (Italy)
2021
Public Health Scotland
2021
SUMMARY Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin (IL)-6, reducing inflammation, and commonly used treat rheumatoid arthritis. We evaluated safety efficacy of tocilizumab in adult patients admitted hospital with COVID-19 evidence both hypoxia systemic inflammation. Methods This randomised, controlled, open-label, platform trial (Randomised Evaluation Therapy [RECOVERY]), assessing several possible treatments hospitalised UK. Those participants...
Cryptococcal meningitis associated with human immunodeficiency virus (HIV) infection causes more than 600,000 deaths each year worldwide. Treatment has changed little in 20 years, and there are no imminent new anticryptococcal agents. The use of adjuvant glucocorticoids reduces mortality among patients other forms some populations, but their is untested cryptococcal meningitis.
Tuberculous meningitis is often lethal. Early antituberculosis treatment and adjunctive with glucocorticoids improve survival, but nearly one third of patients the condition still die. We hypothesized that intensified would enhance killing intracerebral Mycobacterium tuberculosis organisms decrease rate death among patients.We performed a randomized, double-blind, placebo-controlled trial involving human immunodeficiency virus (HIV)-infected adults HIV-uninfected clinical diagnosis...
Abstract Background Little is known about the natural history of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods We conducted a prospective study at quarantine center for disease 2019 in Ho Chi Minh City, Vietnam. enrolled quarantined people with reverse-transcription polymerase chain reaction (RT-PCR)–confirmed SARS-CoV-2 infection, collecting clinical data, travel and contact history, saliva enrollment daily nasopharyngeal/throat swabs (NTSs)...
ABSTRACT Tuberculous meningitis (TBM) is the most severe form of tuberculosis. Microbiological confirmation rare, and treatment often delayed, increasing mortality morbidity. The GeneXpert MTB/RIF test was evaluated in a large cohort patients with suspected tuberculous meningitis. Three hundred seventy-nine presenting to Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, between 17 April 2011 31 December 2012 were included study. Cerebrospinal fluid samples tested by Ziehl-Neelsen...
SUMMARY Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that bind to two different sites on the receptor binding domain SARS-CoV-2 spike protein. We aimed evaluate efficacy safety in patients admitted hospital with COVID-19. Methods In this randomised, controlled, open-label platform trial, several possible treatments were compared usual care hospitalised Eligible consenting randomly allocated (1:1) either standard alone (usual group) or plus...
Background. Penicillium marneffei is an important human immunodeficiency virus (HIV)–associated opportunistic pathogen in Southeast Asia. The epidemiology and the predictors of penicilliosis outcome are poorly understood.
Enteric fever is a major global problem. Emergence of antibacterial resistance threatens to render current treatments ineffective. There little research or public health effort directed toward Salmonella enterica serovar Paratyphi A, because it assumed cause less severe enteric than does S. Typhi. are few data on which base this assumption, known the serovar's susceptibilities, and there no readily available tolerable vaccination.A prospective study was conducted 609 consecutive cases...
Talaromyces marneffei infection is a major cause of human immunodeficiency virus (HIV)-related death in South and Southeast Asia. Guidelines recommend initial treatment with amphotericin B deoxycholate, but this drug has substantial side effects, high cost, limited availability. Itraconazole available oral form, associated fewer unacceptable effects than amphotericin, widely used place amphotericin; however, clinical trials comparing these two treatments are lacking.In open-label,...
Adjunctive dexamethasone reduces mortality from tuberculous meningitis (TBM) but not disability, which is associated with brain infarction. We hypothesised that aspirin prevents TBM-related infarction through its anti-thrombotic, anti-inflammatory, and pro-resolution properties. conducted a randomised controlled trial in HIV-uninfected adults TBM of daily 81 mg or 1000 mg, placebo, added to the first 60 days anti-tuberculosis drugs (NCT02237365). The primary safety endpoint was...
Abstract Background One hundred days after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Vietnam on 23 January, 270 cases were confirmed, with no deaths. We describe the control measures used by government and their relationship imported domestically acquired case numbers, aim of identifying associated successful SARS-CoV-2 control. Methods Clinical demographic data infected timing nature measures, including numbers tests quarantined individuals,...
ABSTRACT Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2 antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety and efficacy convalescent in admitted hospital COVID-19. Methods In this randomised, controlled, open-label, platform trial (Randomised Evaluation Therapy [RECOVERY]) several possible treatments are being compared usual care hospitalised UK. Eligible consenting were randomly allocated receive either plus high...
BackgroundPaediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as in children (MIS-C) emerged April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess effect of intravenous immunoglobulin or corticosteroids compared usual care on duration hospital stay for PIMS-TS and compare tocilizumab (anti-IL-6 receptor monoclonal antibody) anakinra (anti-IL-1 antagonist) those inflammation refractory initial treatment.MethodsWe...
Most cases of cryptococcal meningitis occur in patients with HIV infection: the course and outcome disease apparently immunocompetent is much more poorly understood. We describe a cohort uninfected Vietnamese whom underlying uncommon, relate presenting features characteristics infecting species to outcome.A prospective descriptive study negative based at Hospital for Tropical Diseases, Ho Chi Minh City. All had comprehensive clinical assessment baseline, were cared by dedicated team,...
Tuberculous meningitis (TBM) is the most severe form of extrapulmonary tuberculosis. We developed and validated prognostic models for 9-month mortality in adults with TBM, or without human immunodeficiency virus (HIV) infection.
Background Infectious diseases of the central nervous system (CNS) remain common and life-threatening, especially in developing countries. Knowledge aetiological agents responsible for these infections is essential to guide empiric therapy develop a rational public health policy. To date most data has come from patients admitted tertiary referral hospitals Asia there limited at provincial hospital level where are seen. Methods We conducted prospective Provincial Hospital-based descriptive...
SUMMARY Background Colchicine has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory actions. Methods In this randomised, controlled, open-label trial, several possible treatments were compared with usual care in patients hospitalised COVID-19. Eligible and consenting adults randomly allocated 1:1 ratio to either standard alone or plus colchicine twice daily 10 days until discharge (or one other arms) using web-based simple (unstratified) randomisation allocation...
SUMMARY Background We evaluated the use of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, for treatment patients admitted to hospital because COVID-19. Methods This randomised, controlled, open-label platform trial (Randomised Evaluation COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in hospitalised Eligible and consenting were randomly allocated (1:1) either usual standard care alone (usual group) or plus baricitinib 4 mg once daily by mouth 10 days until...
ObjectiveTo assess the efficacy of gatifloxacin versus cefixime in treatment uncomplicated culture positive enteric fever.DesignA randomized, open-label, active control trial with two parallel arms.SettingEmergency Room and Outpatient Clinics Patan Hospital, Lagankhel, Lalitpur, Nepal.ParticipantsPatients clinically diagnosed fever meeting inclusion criteria.InterventionsPatients were allocated to receive one drugs, Gatifloxacin or Cefixime. The dosages used 10 mg/kg, given once daily for 7...